irritable bowel syndrome. Irritable bowel syndrome with diarrhoea
Conditions
Interventions
Intervention 1: Vitamin D in the intervention group. Intervention 2: Filled with edible paraffin placebo in control group.
Treatment - Drugs
Vitamin D in the intervention group
Filled with edible paraffin placebo in control group
Sponsors
Vice Chancellor for Research,Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria for the study: aged between 18 and 60 years; suffering from irritable bowel syndrome ROME III criteria and completed the questionnaires; their disease severity score is between 175 and 300; BMI Between 18.5 to 34.9; a resident of Tehran; have diarrhea-predominant irritable bowel syndrome with form. Non-inclusion criteria: pregnant women or nursing mothers; a history of gastrointestinal diseases, including IBD, colorectal cancer and...; Gastrointestinal diseases such as celiac disease, is an infection of the gastrointestinal tract and ...; Abdominal surgery or radiation therapy, cholecystectomy, etc. (If your gallbladder is removed, the probability malabsorption of fat and vitamin D absorption.); The use of vitamin D supplements, six months before; Use of now any type of supplement or 3 months; probiotic supplement use; Antidepressants uses (Including serotonin receptor antagonists, tricyclic antidepressants, selective serotonin reuptake inhibitors, etc.); High-dose alcohol and caffeine 24 hours before the test; smoking 48 hours before the test Exclusion criteria: Create any abnormal reactions to supplements; gastrointestinal bleeding; blood in the stool; rapid weight loss ; the level of vitamin D normal (above 30 nmol / L); less than 80 percent of supplements ; no intention to continue cooperation
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quality of life. Timepoint: Before and after 3 months of intervention. Method of measurement: Irritable Bowel Syndrome Quality of Life Questionnaire.;Severity of Clinical symptoms. Timepoint: Before and after 3 months of intervention. Method of measurement: IBS symptom severity questionnaire.;Clinical signs. Timepoint: Before and after 3 months of intervention. Method of measurement: ROME IV questionnaire and World Gastroenterology Organization questionnaire for the diagnosis of irritable bowel syndrome. | — |
Secondary
| Measure | Time frame |
|---|---|
| Anxiety. Timepoint: Before and after 3 months of intervention. Method of measurement: Hospital Anxiety and Depression Scale(HADS).;Serum levels of serotonin. Timepoint: Before and after 3 months of intervention. Method of measurement: Blood serum in terms of nmol /L.;Serum levels of 5-hydroxy indole acetic acid. Timepoint: Before and after 3 months of intervention. Method of measurement: Blood serum in terms of nmol /L. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMasoumeh Khalighi Sikaroudi
Iran University Medical Sceinces
Outcome results
None listed